Abstract The German Psoriasis Registry PsoBest was conducted in 2008 in order to
investigate the long-term outcomes and safety of systemic treatments for moderate-to-severe …

Objective To describe the use of systemic therapy for psoriasis (biologic and nonbiologic
[classic] drugs) in patients not adequately represented in randomized controlled trials …

With the introduction of new systemic drugs for the management of psoriasis, we felt an
obligation in Sweden to establish a trusted tool to monitor their use. We formed PsoReg to …

Background Long-term data are essential to assess the safety of biologic agents for the
treatment of psoriasis. Objective To evaluate the incidence of adverse events of interest …

The introduction of new therapeutic options for the management of psoriasis is a challenge
for the dermatology community, and new tools are needed to face this challenge. This article …

Background Drug survival depends on several factors such as dosing, effectiveness, quality‐
of‐life improvement and safety, and could be seen as an overall marker for treatment …

Summary Background The British Association of Dermatologists (BAD) established a web‐
based pharmacovigilance register to assess the long‐term safety of biologics prescribed for …

Background Registry studies broadly describing the safety of systemic drugs in psoriasis are
needed. Objective To describe the safety findings of the systemic drugs acitretin …

Background Few reported studies compare drug survival in moderate‐to‐severe psoriasis
vulgaris. Objectives To describe and compare drug survival of systemic drugs, including …

Summary Background The German psoriasis registry PsoBest records the long‐term
efficacy, safety, patient benefit and treatment regimens of psoriasis. Patients and methods …